Urachal carcinoma with liver, lung, and brain metastases: benefit of a new combination chemotherapy (bevacizumab, 5-fluorouracil, irinotecan) – case report
J Dekoninck1, P Demetter2, Filip Geurs1, R De Loecker3
1Department of Medical Oncology, Regional Hospital Sint Maria, Halle, Belgium; 2Department of Pathology, Hopital Erasme – Université Libre de Bruxelles (ULB), Anderlecht, Belgium; 3Department of Laboratory, Regional Hospital Sint Maria, Halle, Belgium
Abstract: After failure of cisplatin-based chemotherapy for metastatic urachal carcinoma, a 16-year-old patient presents with diffuse liver-, lung-, and brain metastases. The K-ras mutation is present in the liver as well as in the primary resected specimen. The regimen was therefore changed to bevacizumab, 5-fluorouracil, and irinotecan. This led to a partial response which lasted 7 months.
Keywords: K-ras mutation, urachal cancer, adenocarcinoma